jpolicano

— Appointment supports Noema’s robust clinical-stage pipeline addressing high value CNS disorders — BASEL, Switzerland, November 15, 2023 — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser, M.D., M.B.A has joined the Company as Chief Medical Officer (CMO). “Dr. Lasser brings over 25 years of CNS […]

Oversubscribed financing to support continued development of its diversified pipeline focused on central nervous system disorders Nanna Lüneborg, General Partner at Forbion and Rachel Mears, Partner at Jeito Capital to join Board of Directors Multiple Phase 2b trials in orphan and mainstream CNS indications continue to advance BASEL, Switzerland, March 7, 2023 – Noema Pharma,

BASEL, Switzerland, December 8, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will host a key opinion leader (KOL) webinar, entitled “From Hesitation to Greatness: Understanding Stuttering, its Neurobiology, its Impact on Social and Professional Functioning, and the Quest for Novel Therapies,” on

BASEL, Switzerland, November 9, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Catherine Moukheibir and Ilise Lombardo as independent members of the company’s Board of Directors. Ms. Moukheibir has extensive experience in finance, capital markets and life sciences, having held a number

First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema advancing potentially life-changing therapeutics for patients without satisfactory treatments Basel, August 5, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the initiation of its first clinical trial, a Phase 2a

BASEL, Switzerland, July 7, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, will host a key opinion leader (KOL) webinar on seizures in tuberous sclerosis complex (TSC) on Tuesday, July 20, 2021 at 4pm CET / 10am Eastern Time. The webinar will feature a presentation by Dr

BASEL, Switzerland, May 31, 2021, Basel, Switzerland – Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announces it will attend several investor conferences during June and July. Luigi Costa, Chief Executive Officer, and George Garibaldi, Chief Medical Officer, will present the latest developments at Noema Pharma following the oversubscribed Series